Rosalind Franklin Institute appoints Professor Paul Matthews as new director

The Rosalind Franklin Institute is a national research institute developing new technologies to tackle important health research challenges. Funded by UK Research and Innovation through the Engineering and Physical Sciences Research Council (EPSRC), the Franklin aims to bring about a revolution in imaging which will allow us to see entire cells and tissues in new ways.

Professor Matthews is currently Head of the Department of Brain Sciences at Imperial College London, Director of the UK Dementia Research Institute Centre at Imperial College London and Chair of the UKRI Medical Research Council Neurosciences and Health Board. He brings with him over 30 years of experience working on neurodegenerative disorders, most recently focused on Alzheimer’s disease and multiple sclerosis. He is a world class clinician scientist, trained at the Universities of Oxford and Stanford.

Dame Vivienne Cox, Chair of the Franklin, said: “We are delighted to have appointed Professor Matthews to lead the Franklin into this new phase of development. His experience with all elements of the drug discovery pipeline, from early discovery research to late-stage clinical trials, will bring key insights as we develop and apply our technologies to real biological problems.”

Professor Matthews, said: “The hard work of the first Director and his team have established the Franklin as a unique national resource. I am excited now to lead the Franklin, strengthen partnerships with universities and industry and further realise the Institute’s potential to generate the transformative insights needed to help people live more productive and healthier lives.”

Professor Matthews was the founding Director of two world leading research imaging centres, the University of Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, and GlaxoSmithKline’s Clinical Imaging Centre. He was Vice President for Imaging, and Integrative Medicines Development at GlaxoSmithKline between 2005 and 2014, where he led the late phase development programme.

For his services to neuroscience, Professor Matthews was awarded an OBE in 2008 and elected to the Academy of Medical Sciences in 2014.

Dr Andrew Bourne, Executive Director of Partnerships at the Engineering and Physical Sciences Research Council (EPSRC), said: “I’d like to congratulate Professor Paul Matthews as he takes up his role as director of the Rosalind Franklin Institute. The institute has forged a significant reputation for first-class research and innovation by connecting physical sciences and engineering to life sciences. I’d like to thank Professor James Naismith for his leadership since the creation of the institute in 2018. I’d also like to wish both Professor Matthews and Professor Naismith good luck in their new roles.”

Rebecca Csöndör, a second year PhD student at the Franklin, said: “I was delighted to hear the news that Professor Matthews will be our new Institute Director, especially given his eminent leadership in my field of study. My PhD project focuses on investigating the structural integrity of synapses in the brains of people with Alzheimer’s Disease.”

Professor Matthews will lead the Franklin into its next phase, which will include expanding its work in the tissue domain, and creating new technologies which enable pathology to be imaged and understood across multiple scales.

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

Novel drug and software combo tackles hypertension with personalised treatment

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).


More within